{"url_path":"/sec/dftx/8-k/2026-06-22/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1813814/0001104659-26-076091-index.html","accession_number":"0001104659-26-076091","cik":"0001813814","ticker":"DFTX","issuer_name":"Definium Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1813814/0001104659-26-076091-index.html","primary_entity_key":"0001813814","primary_entity_name":"Definium Therapeutics, Inc."},"word_count":308,"has_tables":true,"body_markdown":"false\n0001813814\nA1\n\n0001813814\n\n2026-06-22\n2026-06-22\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES\nSECURITIES AND EXCHANGE COMMISSION****WASHINGTON, D.C. 20549**\n\n \n\n \n\n \n\n**FORM 8-K**\n\n \n\n \n\n \n\n**CURRENT REPORT**\n\n \n\n**Pursuant to Section 13 or 15(d) of\nthe Securities Exchange Act of 1934**\n\n \n\n**Date of Report (Date of earliest event reported): June 22, 2026**\n\n \n\n \n\n \n\n**Definium Therapeutics, Inc.**\n\n**(Exact name of Registrant as Specified in Its\nCharter)**\n\n \n\n \n\n \n\n**British Columbia**\n**001-40360**\n**98-1582438**\n\n**(State or Other Jurisdiction\nof Incorporation)**\n**(Commission File Number)**\n**(IRS Employer\nIdentification No.)**\n\n \n \n \n \n \n\n**One World Trade Center**\n\n**Suite 8500**\n\n \n\n**New York, New York**\n \n**10007**\n\n**(Address of Principal Executive Offices)**\n \n**(Zip Code)**\n\n \n\n**Registrant’s Telephone Number, Including Area Code: (212) 220-6633**\n\n \n\n**(Former Name or Former Address, if Changed Since\nLast Report)**\n\n \n\n \n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n¨Written\ncommunications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n¨Soliciting\nmaterial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n¨Pre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n¨Pre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\n**Securities registered pursuant to Section 12(b) of\nthe Act:**\n\n \n\n**Title\nof each class**\n \n**Trading\nSymbol(s)**\n \n**Name\nof each exchange on which registered**\n\nCommon Shares\n \nDFTX\n \nThe Nasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities\nExchange Act of 1934 (§ 240.12b-2 of this chapter).\n\n \n\nEmerging growth company x\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨"}